Interventional Psychiatry Fellowship Program

Dr. Bhati is an interventional psychiatrist with expertise in psychiatric diagnosis, psychopharmacology, and neuromodulation. He completed postdoctoral research studying language abnormalities and transcranial magnetic stimulation (TMS) evoked potentials in schizophrenia. He was a principal investigator for the DSM-5 academic field trials, and his research experiences included roles as an investigator in the first controlled clinical trials of deep brain stimulation (DBS) and low-field synchronized TMS for treatment of depression. His current interests include studying magnetic resonance imaging (MRI) and augmented reality to target TMS, vagus nerve stimulation (VNS) for treatment-resistant depression, responsive neurostimulation (RNS) for treatment of impulse and fear-related disorders, and focused ultrasound (FUS) for treatment-resistant obsessive compulsive disorder and depression. Dr. Bhati is also interested in better understanding consciousness and its role in mental illness.

Dr. Buch is a neurosurgeon with fellowship training in epilepsy, functional, and minimally invasive neurosurgery. He is a clinical assistant professor in the Department of Neurosurgery of Stanford University School of Medicine. Dr. Buch focuses his expertise on the open and minimally invasive treatment of epilepsy, low grade brain tumors, movement and neuropsychiatric disorders, facial and body pain syndromes, and other complex neurological conditions. He uses advanced and innovative techniques to treat both adult and pediatric patients. For each patient, he develops a personalized care plan that is designed to be both comprehensive and compassionate. Dr. Buch has conducted extensive research. His interests include restorative network engineering for intellectual and cognitive disability, personalized network-targeting for deep brain stimulation and MRI guided focused ultrasound, and focused ultrasound-mediated delivery mechanisms for gene, stem cell, and molecular therapies. He also is developing technological innovations such as the use of holographic mixed reality and artificial intelligence for visualization and guidance to improve minimally invasive neurosurgical procedures. He has co-authored articles on his research discoveries in the Annals of Surgery, Frontiers in Neuroscience, Epilepsia, Stereotactic and Functional Neurosurgery, Surgical Innovation, Journal of Neurosurgery, and many other journals. Articles focus on developing novel network control theory applications to human brain functions and new techniques and technologies to enhance neurosurgical effectiveness and patient outcomes. He is a contributor to the journals Surgical Innovation and Brain Sciences. He also has co-authored chapters in the books Neurosurgical Atlas, Operative Techniques in Epilepsy Surgery, Deep Brain Stimulation, and The Encyclopedia of Medical Robotics. Dr. Buch has presented the findings of his research at the national conferences of numerous professional associations. Among them are the American Association of Neurological Surgeons, Society for Neuroscience, Congress of Neurological Surgeons, and Society for Imaging Informatics in Medicine. Topics include understanding network mechanisms of cognitive control and advances in the use of augmented reality technology to enhance neurosurgical approaches. For his clinical, research, and academic achievements. Dr. Buch has earned many honors. He has won awards from the American Association of Neurological Surgeons, American Roentgen Ray Society, Congress of Neurological Surgeons, and National Institutes of Health. Dr. Buch is a member of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, World Society for Stereotactic and Functional Neurosurgery, American Association of Stereotactic and Functional Neurosurgery, and Alpha Omega Alpha Medical Honor Society. He holds patents on artificial intelligence systems designed to help guide surgery and on neural control signals for behavioral modification therapy.

Dr. Choi is an interventional and forensic neuropsychiatrist on the Stanford faculty. He received his MD/PhD at UC-San Diego as part of NIH's Medical Scientist Training Program. He received his PhD degree in Neuroscience for work done at the Salk Institute in neural development. Dr Choi is the founding director of Stanford's Forensic Psychiatry Fellowship Program, the first neurolaw-focused forensic fellowship in the world. As a forensic psychiatrist, Dr. Choi specializes in neurolaw, an emerging interdisciplinary field that studies the use and misuse of neuroscience-based evidence in the courtroom. His research interests include the use of functional brain imaging to discern mental states (e.g. lie detection, pain assessment), and the neural basis for moral decision making (e.g. defects in moral reasoning brain centers giving rise to psychopathy). A central question he considers is: how do advances in our knowledge of the neural basis of behavior change perceptions of how offenders should be punished? He has testified as a court-appointed expert, as well as for the prosecution and defense, in many high-profile and complex cases involving psychiatric, neurologic, medical, and medication-related legal claims. Dr. Choi is an active educator, providing seminars to students, attorneys, judges, neuroscientists and clinicians on the importance and relevance of neuroscience and the law. Dr. Choi’s clinical interests include neuromodulatory approaches to treat psychiatric illness, such as the use of transcranial magnetic stimulation (TMS) to treat major depression. He is part of the interventional psychiatry group of Stanford Medicine, conducting clinical work and research to advance the power, precision, and scope of neuromodulation. Dr. Choi is an experienced public speaker, and has given a number of talks to lay and professional audiences on neurolaw, the neuroscience of psychopathy, and the neuroscience of moral decision-making. He is a featured TEDx speaker on the topic "Can Neuroscience Eradicate Psychopathy?"

Dr. Huiqiong Deng is a clinical assistant professor of psychiatry. In addition to a medical degree, she earned a PhD, with a major in rehabilitation science and a minor in neuroscience. Specializing in the treatment of alcohol/substance addiction, interventional and cultural psychiatry, her goal is to help each patient along the journey to achieve optimal health and quality of life. As the co-author of more than a dozen scholarly articles, Dr. Deng’s work has appeared in Psychiatry Research, Journal of Studies on Alcohol and Drugs, American Journal on Addictions, Brain Stimulation, and other publications. Dr. Deng has won numerous honors and awards such as the National Institute on Drug Abuse Young Investigator Travel Award, the Ruth Fox Scholarship from the American Society of Addiction Medicine, and College on the Problems of Drug Dependence Travel Award for Early Career Investigators. In addition, she was selected to attend the Annual American Psychiatry Association Research Colloquium for Junior Investigators. Since she joined faculty at Stanford, Dr. Deng has received research grant support by the Department of Psychiatry and Behavioral Sciences Innovator Grant Program.

Dr. Keller is an Assistant Professor of Psychiatry and Behavioral Sciences at Stanford University and an Assistant Professor at the Veterans Affairs PaloAlto Health Care System (VAPAHCS). He is a member of Stanford Bio-X and the Wu Tsai Neurosciences Institute. Dr. Keller received his MD and PhD in neuroscience from the Medical Scientist Training Program at Albert Einstein College of Medicine. He completed his residency in psychiatry at Stanford University Medical Center focused on interventional psychiatry. Dr Keller has received several grants including the F31, T32, K23, DP5 Early Independence Award, SBIR, and R01 awards. He co-developed a fully automated non-invasive brain mapping technique used across industry and academia, and has run two clinical trials (NCT01829165 and NCT02843373) collecting over 1500 participants across ten clinical centers. Dr. Keller has extensive experience in the assessment and management of individuals with treatment-resistant depression. He has developed methodology for capturing the neurophysiology of human brain networks and the effect of stimulation through invasive and non-invasive electrophysiology.     The overarching goal of Dr. Keller’s Laboratory, the Laboratory for Personalized Neurotherapeutics (kellerlab.stanford.edu) is to improve brain stimulation treatment for neurological and psychiatric disease. His lab focuses on understanding the neural mechanisms of how brain stimulation technologies induce alter brain circuits in an effort to develop novel, personalized, and more effective brain stimulation treatments. His lab combines invasive and noninvasive human electrophysiology to answer these critical questions.

Dr. Daniel Kim is a board-certified geriatric psychiatrist who serves as medical director of the inpatient geriatric psychiatry service and program director of the geriatric psychiatry fellowship. His primary area of interest is in the education of medical students, residents, and fellows in geriatric psychiatry.

Dr. Kratter is an adult psychiatrist and fellowship-trained neuropsychiatrist and clinical assistant professor in the Department of Psychiatry & Behavioral Sciences at Stanford University School of Medicine. He is also director of Invasive Technologies in the Stanford Brain Stimulation Laboratory. His clinical interests include the psychiatric and cognitive aspects of movement disorders like Parkinson's and Tourette's as well as depression, obsessive-compulsive disorder, and non-invasive and invasive neuromodulation for neuropsychiatric illness. His research interests focus on improving outcomes and understanding the mechanisms of neuromodulatory treatments. This includes both clinical and more mechanistic studies using techniques like repetitive transcranial magnetic stimulation (rTMS) and deep brain stimulation in combination with neuroimaging and electrophysiology. He is a co-investigator for such studies focusing on obsessive-compulsive disorder, major depressive disorder, and acute suidical ideation. Dr. Kratter has published articles on topics such as deep brain stimulation for Parkinson’s disease and gene-targeting therapy for Huntington disease. His work has appeared in the Journal of Clinical Investigation, Proceedings of the National Academy of Science, and American Journal of Human Genetics. He also co-authored the chapter on major depression in the textbook Deep Brain Stimulation: Techniques and Practice. Dr. Kratter has presented his work at the annual meetings of the American Neuropsychiatric Association, Hereditary Disease Foundation, and Society for Neuroscience. Topics include cognitive changes following deep brain stimulation for Parkinson’s disease, antipsychotic-induced thrombocytopenia, and mediators of pathology in Huntington’s disease. For his scholarship and research achievements, Dr. Kratter has won multiple honors. They include the Miller Foundation Award for Psychiatric Research. He also won the Ruth L. Kirschstein National Research Service Award from the National Institute of Neurological Disorders and Stroke. He is or has been a member of the American Neuropsychiatric Association, American Society of Clinical Psychopharmacology, American Association for Geriatric Psychiatry, Academy of Psychosomatic Medicine, and Society for Neuroscience.

Dr. Raj specializes in the treatment of mood disorders with an expertise in neuromodulation and in the psychopharmacological management of bipolar disorder. She is co-chief of the mood disorders section and chief of the bipolar clinic. She is the director of education for interventional psychiatry where she manages resident education in ECT and TMS and development of didactics. She is also co-director of the neuroscience curriculum for the psychiatry residency where she has worked to assess and create a new series of interactive lectures. She currently serves on the Board of Directors and the Education Committee of the Clinical TMS society. She is on the Education Committee of the National Neurosciences Curriculum Initiative.

Dr.Sahlem is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences. He is board-certified in general psychiatry and addictions medicine, as well as fellowship-trained in the research and clinical application of neuromodulation-based treatments including repetitive Transcranial Magnetic Stimulation (rTMS), electroconvulsive therapy (ECT), and vagus nerve stimulation (VNS). He additionally has advanced training in the treatment of mood and sleep disorders. In addition to being an active clinician, Dr.Sahlem is a member of the Stanford Brain Stimulation Lab and directs the Addictions Research Section of the Lab. Major areas of study for Dr.Sahlem include: The development of rTMS as a focused treatment for addictive disorders; the development of a novel form of ECT theorized to have reduced cognitive side effects, Focal Electrically Administered Seizure Therapy (FEAST), and; the further development of rTMS for the treatment of mood disorders.

Khalid Salaheldin, MD serves as Clinical Assistant Professor and interventional psychiatrist in the Department of Psychiatry & Behavioral Sciences at Stanford University School of Medicine. Dr. Salaheldin specializes in the management of individuals presenting with early psychosis. His current work at Stanford spans evaluating patients in the early psychosis INSPIRE clinic, inpatient psychiatric unit, and the interventional psychiatry services; alongside teaching, research, and continuing to learn from his patients & colleagues. His treatment philosophy is a holistic and compassionate approach evaluating vital underlying factors alongside pharmacotherapy & neuromodulatory interventions including: sleep, exercise, nutrition, mindfulness, therapy integration, underlying medical issues, substance use, psychosocial history, and importantly patients’ current relationships (including pets of course!). His approach focuses on meeting patients where they are at in their health journey, aligning treatment with their personal goals, and being actively present in their management. Dr. Salaheldin’s research interests include early psychosis interventions, underlying medical causes of psychiatric symptoms, neuromodulation, community/global mental health, spirituality and mental health, healthcare worker mental health, novel psychiatric therapeutics, and mental health parity & policy. Prior coming to Stanford, Dr. Salaheldin’s work as academic chief resident at Northwell Health focused on piloting a consult liaison service for first episode psychosis that compassionately assists patients and their families from once they enter the emergency room, through their inpatient admission and into the outpatient setting. We kindly request that patients do their best to provide the clinic with their previous blood work, imaging reports and medical history paperwork prior to the appointment in order to have the most complete initial evaluation. “True compassion means not only feeling another's pain, but also being moved to help relieve it. ” —Daniel Goleman

Dr. Barbara Sommer specializes in geriatric psychiatry, treating older patients suffering from depression, anxiety, psychosis, and cognitive disorders, often in the context of concomitant medical illnesses. She has practiced in both inpatient and outpatient settings for over thirty years and she has a special interest in the unique primary and side effects of psychiatric medications in older patients also being treated for non-psychiatric disorders. She also is a member of the electroconvulsive therapy (ECT) service.

Dr. Williams is an Associate Professor within the Department of Psychiatry and Behavioral Sciences and the Director of the Stanford Brain Stimulation Lab. Dr. Williams has a broad background in clinical neuroscience and is triple board-certified in general neurology, general psychiatry, as well as behavioral neurology & neuropsychiatry. In addition, he has specific training and clinical expertise in the development of brain stimulation methodologies. Themes of his work include (a) examining the use of spaced learning theory in the application of neurostimulation techniques, (b) development and mechanistic understanding of rapid-acting antidepressants, and (c) identifying objective biomarkers that predict neuromodulation responses in treatment-resistant neuropsychiatric conditions. Dr. Williams' work has resulted in an FDA clearance for the world's first non-invasive, rapid-acting neuromodulation approach for treatment-resistant depression. He has published papers in high-impact peer-reviewed journals including Brain, American Journal of Psychiatry, and the Proceedings of the National Academy of Science. Results from his studies have gained widespread attention in journals such as Science and New England Journal of Medicine Journal Watch as well as in the popular press and have been featured in various news sources including Time, Smithsonian, and Newsweek. Dr. Williams received two NARSAD Young Investigator Awards in 2016 and 2018 along with the 2019 Gerald R. Klerman Award. Dr. Williams received the National Institute of Mental Health Biobehavioral Research Award for Innovative New Scientists in 2020.